Thompson CM, Bichteler A, Rager JE, Suh M , Proctor DM, Haws LC, Harris MA. 2016. Comparison of in vivo genotoxic and carcinogenic potency to augment mode of action analysis: Case study with hexavalent chromium. Mut Res/Genet Toxicol Environ Mutagen 800-801(April):28-34; doi: 10.1016/j.mrgentox.2016.01.008 .
View Abstract
Publication: Manuscripts
/ Topics: carcinogens , chromium , mode of action
Lowe KA, Danese MD, Gleeson ML, Langeberg WJ, Kelsh MA . 2016. Racial and ethnic variability in the prevalence and incidence of comorbidities associated with gastric cancer in the United States. J Gastrointest Cancer 47(2):168–181; doi: 10.1007/s12029-016-9809-5 .
View Abstract
Publication: Abstracts and Presentations
/ Topics: Cancer , Epidemiology
Hummel HD, Topp MS, Chang ET, Chia VM, Kelsh MA , Doemland ML, et al. 2016. Adverse events in adults with relapsed or refractory acute lymphoblastic leukemia (ALL): A literature review of recent clinical trials. J Leuk 4(1):208; doi: 10.4172/2329-6917.1000208 .
View Abstract
Publication: Manuscripts
/ Topics: Cancer , Epidemiology
Erichsen R, Kelsh MA , Oliner KS, Nielsen KB, Frøslev T, Lænkholm AV, et al. 2016. Prognostic impact of tumor MET expression among patients with stage IV gastric cancer: A Danish cohort study. Annals of Epidemiol 26(7):500–503.
View Abstract
Publication: Manuscripts
/ Topics: Cancer , Epidemiology
Garabrant DH, Alexander DD, Miller PE, Fryzek JP, Boffetta P, Teta MJ, … Kelsh MA , et al. 2016. Mesothelioma among motor vehicle mechanics: An updated review and meta-analysis. Ann Occup Hyg 60(1):8–26.
View Abstract
Publication: Manuscripts
/ Topics: Cancer , Epidemiology
Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R, … Kelsh M , et al. 2016. International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101(12):1524–1533; doi: 10.3324/haematol.2016.144311 . PMID: 27587380.
View Abstract
Publication: Manuscripts
/ Topics: Cancer
Gökbuget N, Kelsh M , Chia V, Advani A, Bassan R, Dombret H, et al. 2016. Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473.
View Abstract
Publication: Manuscripts
/ Topics: Cancer
Kelsh MA . Evaluating biosimilars in observational data: Some methodological considerations. Presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE), Dublin, Ireland, August 25–28, 2016.